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Vegge A, Thymann T, Lund P, Stoll B, Bering SB, Hartmann B,
Jelsing J, Qvist N, Burrin DG, Jeppesen PB, Holst JJ, Sangild PT.
Glucagon-like peptide-2 induces rapid digestive adaptation following
intestinal resection in preterm neonates. Am J Physiol Gastrointest
Liver Physiol 305: G277–G285, 2013. First published June 13, 2013;
doi:10.1152/ajpgi.00064.2013.—Short bowel syndrome (SBS) is a
frequent complication after intestinal resection in infants suffering
from intestinal disease. We tested whether treatment with the intesti-
notrophic hormone glucagon-like peptide-2 (GLP-2) increases intes-
tinal volume and function in the period immediately following intes-
tinal resection in preterm pigs. Preterm pigs were fed enterally for 48
h before undergoing resection of 50% of the small intestine and
establishment of a jejunostomy. Following resection, pigs were main-
tained on total parenteral nutrition (TPN) without (SBS, n  8) or
with GLP-2 treatment (3.5 g/kg body wt per h, SBSGLP-2, n 7)
and compared with a group of unresected preterm pigs (control, n 
5). After 5 days of TPN, all piglets were fed enterally for 24 h, and a
nutrient balance study was performed. Intestinal resection was asso-
ciated with markedly reduced endogenous GLP-2 levels. GLP-2
increased the relative absorption of wet weight (46 vs. 22%), energy
(79 vs. 64%), and all macronutrients (all parameters P  0.05). These
findings were supported by a 200% increase in sucrase and maltase
activities, a 50% increase in small intestinal epithelial volume (P 
0.05), as well as increased DNA and protein contents and increased
total protein synthesis rate in SBSGLP-2 vs. SBS pigs (100%,
P  0.05). Following intestinal resection in preterm pigs, GLP-2
induced structural and functional adaptation, resulting in a higher
relative absorption of fluid and macronutrients. GLP-2 treatment may
be a promising therapy to enhance intestinal adaptation and improve
digestive function in preterm infants with jejunostomy following
intestinal resection.
neonatal short bowel syndrome; glucagon-like peptide-2; premature;
intestine
SHORT BOWEL SYNDROME (SBS) is a condition characterized by
malabsorption, diarrhea, dehydration, and malnutrition result-
ing from excessive loss of absorptive area following intestinal
resection. In neonates, intestinal resection can be a conse-
quence of congenital anomalies or necrotizing enterocolitis
(NEC), a serious gastrointestinal inflammatory condition that
mainly affects preterm infants. NEC is the primary cause of
neonatal SBS (17) and occurs in 5–10% of hospitalized pre-
term infants (46). No effective treatment of neonatal SBS is
available, and long-term parenteral nutrition (PN) is often
needed (12). However, long-term PN can lead to catheter-
related bloodstream infection, thrombosis, intestinal failure-
associated liver disease, as well as gastrointestinal complica-
tions (15). Furthermore, clinical trials with growth factor pep-
tides, such as growth hormone, have shown limited efficacy in
reducing the need for PN (11).
Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid pep-
tide, secreted by the enteroendocrine L cells, which indirectly
or directly stimulates intestinal growth and nutrient absorption
(7–9, 48). The rapid intestinal growth and maturation in neo-
nates appears to be GLP-2 mediated (32), and exogenous
GLP-2 is known to stimulate intestinal brush-border enzyme
expression and decrease apoptosis and proteolysis in preterm
pigs (4, 31). Furthermore, GLP-2 increases nutrient absorption
(37) and stimulates intestinal blood flow in piglets (13, 14).
In adult SBS rats, GLP-2 has been shown to increase bowel
weight, villus height, and crypt cell proliferation (27, 28, 41).
In adult mice, resection causes expansion of intestinal stem
cells (5), and early postsurgical GLP-2 treatment augments this
stem cell expansion (10). However, the exact cellular mecha-
nism of action of GLP-2 remains unclear (33). In human adults,
GLP-2 improves nutritional status in patients with SBS, both
when provided as the native GLP-2 (20) and as a long-acting
analog resistant to degradation by dipeptidyl peptidase-4
(DPP-4) (19, 23, 24).
The physiological role and therapeutic potential of GLP-2
for the neonatal SBS gut, particularly after preterm birth,
remains to be established. A single study has examined the
effect of GLP-2 treatment in a juvenile pig SBS model and
reported decreased brush-border enzyme activities, villous at-
rophy, and decreased weight gain in the GLP-2-treated animals
(29). In contrast, increasing plasma GLP-2 levels by supple-
menting total parenteral nutrition (TPN) with short-chain fatty
acids augmented mucosal growth after intestinal resection in
neonatal pigs (1). An important aspect of all previously re-
ported animal SBS studies is that they have employed a
surgical model with resection of the majority of the small
intestine (50–80%), leaving the ileum and colon in continuity
(26, 27, 29). This procedure elevates the endogenous GLP-2
release after resection (26, 27, 29), as shown also in adult
patients with SBS (21, 24). In a recent study using neonatal
pigs, an ileal resection model was described along with the
well-established jejunal resection model, but both models still
had a colon in continuity (44). Here the ileum was found to be
important for intestinal adaptation as well, meaning not just the
colon plays a role, as supported by clinical findings (6).
However, extensive intestinal resection in neonates most often
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results in a proximal stoma at least for some weeks or months.
The removal of the ileum and colon from the luminal nutrient
flow may lead to decreased endogenous GLP-2 release and
likely contributes to poor intestinal adaptation in these infants.
We hypothesized that a 50% intestinal resection with a jeju-
nostomy in premature piglets would lead to severe compromise
of intestinal function and decreased GLP-2 release. Further-
more, we hypothesized that early postsurgical treatment with
exogenous GLP-2 treatment would stimulate intestinal func-
tions and adaptation, leading to improved nutrient absorption.
MATERIALS AND METHODS
Animals. Preterm pigs (Danish LandraceYorkshireDuroc) were
obtained from two litters delivered by Cesarean section (2) at 92% of
gestation, showing signs of prematurity as previously established (35).
When stable respiration was attained, the piglets were transferred to
infant incubators. The pigs were fitted with vascular and orogastric
catheters and given maternal plasma to ensure immunization (35). The
pigs were fed bovine colostrum for 48 h as boluses of 15 ml/kg body wt
per 3 h. On postnatal day 2, enteral feeding was stopped 6 h before
surgery. TPN was initiated 30 min before anesthesia.
Surgical procedures. Pigs were stratified into three groups: unre-
sected controls (n 5), SBSGLP-2 (n 7), and SBSvehicle (n 8).
Pigs were given methadone (0.1 mg/kg im) and intubated, and anesthesia
was induced and maintained with inhalation of isofluorane (1–2%, Isoba;
Schering-Ploug Animal Health, Ballerup, Denmark). Through a lower
left paramedian incision, the ileocecal plicae was located. The ileum was
divided, and the distal end was ligated with a 4-0 monocryl (Monocryl,
Ethicon; Johnson & Johnson Nordic, Birkerød, Denmark) at the ileocecal
junction. The distal small intestine was resected corresponding to 50% of
total small intestinal length. Total intestinal length was estimated from a
series of previous studies in preterm pigs as 280 cm/(BW0.60). A 0.5-cm
everted stoma was created at the skin level in the left subcostal region
with Monocryl 4-0 sutures. The abdominal incision was closed in layers
with interrupted 3-0 sutures in the fascia (VICRYL, Ethicon; Johnson &
Johnson Nordic), and a continuous nonabsorbable 3-0 suture (Ethilon,
Ethicon; Johnson & Johnson Nordic) in the skin. The skin around the
stoma was cleaned with acetone for optimal stoma bag attachment, and
Eakin wound pouch (839260; Focuscare, Randers, Denmark), was
attached. For optimal skin contact and to prevent leakage of stoma
fluids, a Hollister Adapt Paste (Dansac & Hollister, Fredensborg,
Denmark) was used. The stoma bags were changed when needed and
at least every 24 h.
Twelve hours before the surgery and every 12 h for the following
3 days, animals received ampicillin (50 mg/kg body wt; Pentrexyl;
Bristol-Myers Sqibb, Bromma, Sweden) and gentamycin (5 mg/kg
body wt; Hexamycin; Sandoz A/S, Copenhagen, Denmark), both
given intramuscularly. Intramuscular analgesic was given every 12 h
following surgery for 3 days (buprenorphine 0.06 mg/kg body wt;
Temgesic; Reckitt Benckiser Pharmaceuticals, Slough, United King-
dom). After surgery, piglets were given TPN at a dosage of 4 ml/kg
body wt per hour for 24 h and increased daily over the following days
by 1 ml/kg body wt per hour. The TPN used was Nutriflex lipid plus
(Braun, Melsungen, Germany), adjusted to piglets’ needs with added
amino acids (Vamin; Fresenius Kabi, Uppsala, Sweden) to provide the
following: energy: 300–600 kJ/kg body wt per day; amino acids:
4.3–8.6 g/kg body wt per day; carbohydrate: 6.9–13.8 g/kg body wt
per day; lipid: 3.0–6.0 g/kg body wt per day. Human native GLP-2
(1–33) (kindly donated by Dr. Lars Thim, Novo Nordisk, Bagsværd,
Denmark) was dissolved in 0.1% human serum albumin and injected
into the TPN and given as a continuous infusion of 3.5 g/kg body wt
per hour. In addition, 2 ml/kg body wt per hour of 0.9% NaCl was
given intravenously to keep animals hydrated. Piglets were weighed
daily and clinically evaluated for signs of general discomfort, infec-
tion, dehydration, or edema resulting from excessive hydration.
In vivo galactose test and nutrient balance study. On day 4 after
resection, each pig received 15 ml/kg body wt of a 5% galactose
solution in 0.9% saline through the orogastric feeding tube. Plasma
samples were collected before and at 20 min after the galactose bolus.
The plasma was separated, deproteinized using perchloric acid, and
analyzed for concentrations of galactose by the formation of NADH
from NAD by galactose dehydrogenase (Boehringer Mannheim,
Darmstadt, Germany). Following the galactose test, a 24-h enteral
nutrition balance study was conducted for the two resected groups,
where the pigs were given 7.5 ml/kg per h of bovine colostrum (590
kJ/kg body wt per day). Stoma output was collected throughout the
balance period and quantified. After mixing all collections from each
pig, we analyzed the energy content by bomb calorimetry and carbo-
hydrate concentration by the Englyst method, the protein concentra-
tion by the Kjeldahl method, and the fat concentration by Van der
Kamer titration, as previously described (22), with relative absorption
calculated as: (intake output)/(intake 100). All animal procedures
were approved by the Danish Animal Experimentation Inspectorate in
accordance with the Council of Europe Convention ETS 123.
Tissue collection. By the end of the 24-h enteral balance study,
tissue protein synthesis was measured as described previously using
stable isotopes (4). Briefly, piglets were given an intra-arterial infu-
sion of L-phenylalanine (1.5 mmol/kg containing 0.15 mmol/kg
L-[ring-13C6] phenylalanine; Cambridge Isotopes Laboratories, Woburn,
MA). Thirty minutes after isotope infusion, pigs were anesthetized,
blood was drawn by cardiac puncture, and the pigs were euthanized
with pentobarbitone (43). The small intestine, from the pyloric sphinc-
ter to the jejunostomy, was rapidly excised and placed on an ice-cold
metal plate in a relaxed state. The total length was measured, and the
small intestine was weighed. The remaining distal small intestine was
sampled for histology and stereology using systematic uniform ran-
dom sampling. A total of nine sections were taken throughout the
intestine starting from a predetermined random start site and with a set
sampling distance (total length/9). At each site, a 0.5-mm transverse
biopsy was taken and fixed in 4% neutral buffered paraformaldehyde.
Just proximal to the resection site, 10 cm of intestine was taken and
placed in ice-cold Ringer for ex vivo nutrient absorption (see details
below), and pieces from the proximal and distal segment were snap
frozen in liquid nitrogen. In addition, 10 cm of duodenum and 10 cm
of jejunum was removed and opened along the length, the mucosa was
scraped off with a plastic slide, and the proportion of mucosa was
determined after drying both the mucosa and the remaining intestine
for 72 h at 60°C. The colon, heart, liver, lung, spleen, and stomach
were weighed.
Intestinal protein synthesis. Frozen tissue samples were homoge-
nized and deproteinized using 2M perchloric acid, and the perchloric
acid-soluble and the acid-insoluble fractions were analyzed by mass
spectrometry. The acid-insoluble fraction was hydrolyzed using 6 M
HCl for 24 h before gas chromatography-mass spectrometry analysis.
In the two tissue pools, the isotopic enrichment of L-[ring-13C6]
phenylalanine] was determined by the N-propyl ester heptafluorobu-
tyramide derivative using methane-negative chemical ionization. The
analyses were performed on a 5890 series II gas chromatograph linked
to a 5989B quadrupole mass spectrometer (Hewlett-Packard, Palo
Alto, CA). Tissue samples were analyzed for protein content using the
bicinchoninic acid method (Pierce, Rockford, IL).
Ex vivo absorption and mucosal enzyme activity. One snap-frozen
sample from the proximal and distal remnant small intestine from
each pig was homogenized in 1.0% Triton X-100 (6 ml/g). The
homogenates were assayed for disaccharidases (lactase, maltase, and
sucrase) and aminopeptidase N, (ApN), aminopeptidase A (ApA), and
DPP-4 activities, as previously described (36). The amount of sub-
strate hydrolyzed in 1 min at 37°C was set to represent one unit of
enzyme activity and was expressed per gram of intestine.
For ex vivo assessment of nutrient absorption, intestinal segments
were obtained from the distal remnant small intestine at euthanasia.
The tissue sections were kept in ice-cold Ringer solution before they
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were everted, cut into 1-cm pieces, and mounted on stainless steel
rods. The sections were incubated in aerated Ringer nutrient solution
for 4 min at 37°C. The capacity for nutrient uptake was measured for
glucose and leucine, both at 5 and 50 mmol/l. The accumulation of
nutrients by the mucosa was quantified by adding traceable amounts
of either [U-14C] D-glucose (1.0 l/10 ml) or L-[4,5–3H(N)]-leucine
(2.0 l/10 ml). The use of tracer-labeled D-glucose provides a sensi-
tive indicator of the activities of the apical membrane glucose trans-
porter, sodium-dependent glucose transporter 1. For leucine, the
uptake represents both passive influx and active transport by carrier
systems.
Plasma GLP-2 and amino acid measurements. Plasma samples for
GLP-2 measurements were taken at 0, 48, 96, and 120 h after surgery.
All samples were extracted in a final concentration of 75% ethanol
before GLP-2 measurements. GLP-2 was measured with an NH2-
terminal specific antiserum (code no. 92160), measuring only GLP-2
with an intact NH2 terminus, as previously described (18). For
standards, we used recombinant human GLP-2, and the tracer was rat
GLP-2 with an Asp33 - Tyr33 substitution. For amino acid concen-
tration measurements, plasma samples were mixed with an equal
volume of methionine sulfone (4 mM) as internal standard and
centrifuged at 10,000 g for 30–60 min at 4°C through a 10-kDa cutoff
filter. The filtrate was dried, and the amino acids were analyzed by
reverse-phase high-pressure liquid chromatography of their phenyl-
isothiocyanate derivatives (PicoTag; Waters, Woburn, MA) (42).
Histology, stereology, and Western blot. The fixed samples were
embedded in paraffin, cut into 5-m thin paraffin sections, and stained
with hematoxylin and eosin for morphometry measurements. An
Olympus microscope running new CAST software (Visiopharm, Hør-
sholm, Denmark) was used for quantitative stereological analysis. The
volume of the intestinal layers was estimated using the Cavalieri
principle, volume  t * Ap * p, where t is the distance between the
sections, p is the number of points that fall on the region of interest,
and A is the area associated with each test point in the point grid. The
grid was designed to provide a total of 100–200 hits per region, which
is sufficient to give a coefficient of error 5% (16). Villus height and
crypt depth were determined on digital images acquired with an
Axiophot microscope (Carl Zeiss, Oberkochen, Germany) and ana-
lyzed with NIH image software version 1.60 (SoftWoRx Explorer
version 1.1; Applied Precision, Issaquah, WA). A total of 10–15
well-oriented villus and crypts, throughout the remnant intestine, were
measured, and the values were averaged for each sample.
Slides were deparaffinized, endogenous binding sites were blocked
in 0.6% H2O2, and antigen retrieval was conducted using heat-
induced epitope retrieval in Tris-EGTA buffer (pH 8.0). Mouse
monoclonal anti-KI67 (MIB-1; Dako, Glostrup, Denmark) was added
(dilution 1:200) and incubated overnight at 4°C. The slides were
developed after incubation in primary antibody enhancer, and addition
of horseradish peroxidase polymer and the 3-amino-9-ethylcarbazole
power vision were used for detection. Thereafter, the slides were
counterstained in hematoxylin. The slides were counted using a
stereological counting frame in newCAST (Visiopharm, Hørsholm,
Denmark).
Equal amounts of protein samples were separated on SDS-PAGE,
transferred to a nitrocellulose membrane, and incubated with primary
antibody: cleaved caspase 3 (CC3), proliferating cell nuclear antigen
(PCNA), and GAPDH overnight. This was followed by a 1-h incu-
bation with secondary antibody, and the membranes were washed and
developed with enhanced chemiluminescence (ECL-plus; Amersham,
Piscataway, NJ), visualized using a ChemiDoc (UVP, Upland, CA).
Statistical analysis. Time series data were analyzed by the MIXED
procedure in SAS using a Gaussian spatial correlation (version 9.2;
Fig. 1. A: development in body weight (BW) after resection. SBS, short bowel syndrome; TPN, total parenteral nutrition; EN, enteral nutrition. B and C: intestinal length
and mass of remnant small intestine. D: plasma glucagon-like peptide (GLP)-2 concentrations before and after resection. E: in vivo enteral balance. F: ex vivo nutrient
uptake of glucose and leucine. Data are presented as mean  SE. Significant difference between groups (*P  0.05; **P  0.01; ***P  0.001).
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SAS institute, Cary NC). All other analyses were done using the
statistical programming language R. Litter and pig were set as random
variables, and treatment and section were set as explanatory variables.
Post hoc comparisons were done with Wald testing with single-step
P value adjustment for multiple comparisons. When residual variance
heterogeneity was detected, the data were log-transformed before
analysis. Data are reported as means  SE with a P value 0.05
considered significant for all analyses.
RESULTS
Body weight and organ growth. Relative to controls, the two
resected groups showed a decreased weight gain from 3 days
after resection (Fig. 1A and Table 1). Both SBS groups had a
transient hypersecretion after surgery, but this resolved within
the first days. Only transient episodes of hypoglycemia and
alkalosis were seen during the experimental protocol. This was
corrected by increasing TPN and sodium chloride to achieve
normal plasma glucose (2.2  0.3 mmol/l), pH (7.36  0.03)
and base excess (1.2  1.9 mmol/l) across groups.
At euthanasia, the relatively small intestinal weight and
percentage of mucosa were increased in the SBSGLP-2
group, compared with SBS (Fig. 1B, Table 1), with no signif-
icant change in relative length (Fig. 1C). The resected segment
in the SBS group was similar in length to the segment excised
at euthanasia, and the two resected groups had higher relative
spleen weight and lower colon weights, compared with the
control (Table 1).
Plasma GLP-2. Before resection, the three groups had sim-
ilar levels of circulating GLP-2 (	45 pM, Fig. 1B). Within the
first 2 days after resection and transition to TPN, GLP-2 values
in the SBS group decreased (P  0.001), and, from 48 h after
resection and throughout the experiment, the GLP-2 values
remained lower than controls (P  0.05). During the enteral
balance study, a significant increase in GLP-2 occurred in the
control group but not in the two resected groups. The
SBSGLP-2 group had markedly elevated GLP-2 levels (P 
0.001) throughout the study (2,000–3,000 pM) (Fig. 1D).
In vivo nutrient absorption. GLP-2 decreased the absolute
stoma loss of fluids (wet weight), energy, and the individual
macronutrients (P 0.05, Table 2), leading to a higher relative
absorption of fluid, energy, and all macronutrients in the
SBSGLP-2 group, relative to SBS (Fig. 1E). There was no
significant difference in the absolute nutrient balances for
either fluid or macronutrients. No differences were observed in
the acute galactose absorption test with similar circulating
levels of galactose 20 min after a galactose bolus (	1.3  0.2
mmol/l) in all groups. Ex vivo tissue nutrient uptake showed no
differences in uptake of either glucose or leucine among the
three treatment groups (Fig. 1F).
Intestinal protein synthesis and plasma amino acids. By the
end of the experiment, the GLP-2 treatment had increased the
small intestinal DNA and protein content to levels similar to
those in intact controls, and both GLP-2SBS and controls
had a high level of intestinal DNA (160 vs. 86 mg/kg body wt,
P  0.05) and protein content (3.2–3.5 vs. 1.9 g/kg body wt,
P  0.05). Both resected groups had lower FSR than unre-
sected control pigs (Fig. 2A), but, calculated at absolute rates of
protein synthesis, GLP-2 increased protein synthesis values,
relative to SBS alone (Fig. 2D). Increased stomach protein
content was also observed in the SBSGLP-2 compared with
the other groups (Table 3).
GLP-2 induced a marked upregulation of circulating levels
of citrulline, arginine, and ornithine to the levels of unoperated
pigs (Fig. 2, B, C, and E). This upregulation was specific for
the citrulline-arginine-ornithine cycle, and the two SBS groups
Table 1. Body and organ weights
Control SBS SBSGLP-2
Birth body weight, g 993  119 1130  66 1100  52
Postsurgical body weight, g 1017 110 1068  79 1044  47
Final body weight, g 1385 182 1207  75 1103  42
Average daily weight gain, g/kg per day 75  16† 19  6* 12  9*
Resected intestinal length, cm/kg body wt NA 137.6 5.9 138.2  4.2
Resected intestinal weight, g/kg body wt NA 14.19 0.48 14.15 0.59
Proximal small intestinal mucosa, % 70.1  2.4† 62.6  2.7* 70.6  1.6†
Colon, g/kg body wt 8.9  1.9† 4.9  0.7* 5.2  0.8*
Stomach, g/kg body wt 5.0  0.3 5.8  0.6 6.5  1.2
Liver, g/kg body wt 23.2  0.6 26.6  1.9 27.9  2.4
Spleen, g/kg body wt 2.2  0.3* 3.8  0.7† 2.6  0.3*†
Kidneys, g/kg body wt 8.7  0.5* 9.8  0.5*† 10.9  0.5†
Lungs, g/kg body wt 24.2  2.7 28.0  2.7 26.3  2.2
Heart, g/kg body wt 7.2  0.6 8.1  0.5 7.2  0.8
Values mean  SE (n  5–8). *†Values significantly different (P  0.05). SBS, short bowel syndrome; GLP, glucagon-like peptide; NA, not assessed.
Table 2. Twenty-four-hour enteral nutrient balance study
SBS SBSGLP-2 P Value
Wet Weight, ml/day
Intake 197.2 14.4 181.2 6.5 0.27
Stoma output 153.2 21.7 99.3 15.8 0.04
Absolute absorption 44.2 18.9 81.9 13.0 0.09
Energy, kJ/day
Intake 788.0 57.1 724.0 25.3 0.28
Stoma output 279.4 42.9 157.5 24.6 0.01
Absolute absorption 508.6 64.2 566.6 21.8 0.36
Protein, kJ/day
Intake 376.1 27.3 345.1 12.3 0.27
Stoma output 151.5 18.2 91.1 11.4 0.01
Absolute absorption 224.6 26.7 254.0 11.4 0.29
Fat, kJ/day
Intake 299.5 21.7 274.8 9.8 0.27
Stoma output 105.7 21.7 51.8 10.9 0.02
Absolute absorption 193.7 29.0 222.0 10.4 0.31
Carbohydrate, kJ/day
Intake 93.6 7.0 85.9 3.3 0.29
Stoma output 13.1 2.1 8.5 0.9 0.03
Absolute absorption 80.6 6.3 77.4 3.0 0.63
Values are means  SE, n  6–7.
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showed marked decreases in essential amino acids compared
with controls (Fig. 2F), with no effect of GLP-2. A similar
pattern was observed for nonessential amino acids (Table 4).
Ex vivo digestive enzymes and nutrient absorption. We next
examined functional parameters, and intestinal resection did
not alter the activity of brush border enzymes, relative to
unresected control pigs (Fig. 3). However, GLP-2 induced a
marked increase in the activity of brush border enzymes,
especially in the proximal part of the remnant intestine (Fig. 3)
relative to SBS. This was most pronounced for sucrase and
maltase activities (300%, Fig. 3, A and B). GLP-2 induced a
marginal increase in proximal lactase activity (Fig. 3C). GLP-2
induced ApN and DPP-4 activities (200%, Fig. 3, C and D),
whereas there was no effect on ApA activity (Fig. 3F).
Histology and Western blot. In parallel with the changes in
gut mass, we observed an increase in total small intestinal
volume in SBS-GLP-2-treated neonates compared with SBS
(Fig. 4A). Subanalyses of the cellular layers revealed further
that this difference was mainly driven by an increased mucosa
volume, as no significant changes were observed in the sub-
mucosa, serosa, or muscularis layers (Fig. 4A). The marked
increase in mucosa volume is probably related to an increased in
villus surface area as indicated by the observed differences in
villus height and crypt depth in the SBSGLP-2 compared with
the other groups (Fig. 4, B and C). No significant differences in
total number of proliferative cells were seen among groups
(data not shown), and a small difference was seen in number of
Ki67-positive cells per crypt area between controls and
Fig. 2. A and D: fractional and absolute protein synthesis rate in remnant intestine. B, C, E, and F: plasma levels of citrulline, ornithine, arginine, and essential
amino acids, respectively. Data are presented as means  SE. Significant difference between groups (*P  0.05; **P  0.01; ***P  0.001).
Table 3. DNA, protein concentration, FSR, and ASR in the stomach, liver, and muscle
Control SBS SBSGLP-2
Stomach
DNA content, mg/kg body wt 29.0  3.9 27.4 4.1 34.8 2.6
Protein content, g/kg body wt 0.45  0.0* 0.52 0.1* 0.69 0.1†
FSR, %/day 34.0  1.9 32.5 3.5 34.4 6.8
ASR, g/kg body wt per day 0.14  0.0 0.17 0.0 0.24 0.1
Liver
DNA content, mg/kg body wt 110.5  4.0 126.7 4.9 119.8 8.3
Protein, g/kg body wt 3.3  0.1 4.00 0.3 4.3 0.4
FSR, %/day 53.9  3.9 59.8 5.6 58.5 3.0
ASR, g/kg body wt per day 1.8  0.1 2.5 0.5 2.5 0.4
Muscle
DNA concentration, g/mg 4.1 0.3 3.9 0.2 4.4 0.2
Protein concentration, g/mg 84.2  2.7 88.9 4.7 91.9 3.4
FSR, %/day 18.0  4.2 17.5 6.8 17.9 3.6
Values mean  SE (n  5–8). *†Values are significantly different (P  0.05). FSR, fractional synthesis rate; ASR, absolute synthesis rate.
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SBSGLP-2 (Fig. 4D). These findings were supported by
Western blot for CC3 and PCNA, which showed no difference
(Fig. 4E).
DISCUSSION
SBS is a well-known complication following intestinal re-
section in infants suffering from congenital anomalies or NEC
(47). In adult patients with SBS, exogenous GLP-2 improves
intestinal adaptation and stimulates intestinal function (20), but
evidence is lacking regarding the effects of GLP-2 in SBS
newborns. GLP-2 stimulates growth and function of the intact
intestine of TPN-fed preterm and term pigs (30, 31), but the
efficacy appears diminished in preterm pigs (34). In this study,
we combined an immature state of the intestine with SBS and
jejunostomy in preterm pigs. We document that supply of
exogenous GLP-2 in the days just after resection induces
marked improvements in intestinal adaptation and function.
A commonly used clinical index of intestinal function in
patients with SBS is the net enteral nutrient uptake, which can
diminish the need for parenteral nutrition. We found that
GLP-2 treatment decreased the daily stoma losses of fluid and
macronutrients, which translated into significantly increased
relative nutrient absorption of fluid and all macronutrients. In
principle, the GLP-2-induced improvement in relative absorp-
tion could result from direct antisecretory or antidiarrheal
effects. The findings that GLP-2 increases the relative absorp-
tion of especially fluid and protein are also supported by
clinical studies in adult patients with SBS (20), whereas the
effects on enteral balance of antisecretory agents (e.g., raniti-
dine) are primarily related to fluid (25). Our ex vivo data for
nutrient absorption and digestive enzymes suggest that the
improved nutrient balance is likely due to increased digestive
capacity, rather than transport-mediated nutrient uptake per se.
Our data suggest that the important effect seen in enteral
nutritional balance is mediated via the combined effect of a
marked increase in functional tissue mass and a stimulation of
some functions of intestinal tissue, such as (e.g., brush border
enzyme activities) but not hexose absorption capacity. Collec-
tively, the results in this study on preterm SBS piglets suggest
Table 4. Free amino acids in plasma (M)
Control SBS SBSGLP-2
Alanine 414.7  44.0 433.9 56.9 527.7  162.8
Asparagine 179.4 39.7† 48.7 12.3* 73.0  8.4*
Aspartic acid 56.0 9.7 39.7  8.7 36.2  4.1
Cysteine 902.7 101.0 943.4 94.8 1106.4 232.8
Cystine 22.2  6.9 21.5  4.1 21.4  4.9
Glutamine 269.7 30.1 194.3 25.2 225.8  79.5
Glutamic acid 143.3 12.3 163.59 14.7 126.1  13.6
Glycine 913.8 58.7 611.8 113.1 673.6  136.3
Histidine 72.0 8.8 50.6  3.3 54.4  13.2
Isoleucine 244.0 34.9† 143.1 10.6* 159.5  13.2*
Leucine 341.7 46.0† 205.6 12.9* 232.4  24.73*
Lysine 328.4 47.5† 179.7 17.3* 232.8  53.2*†
Methionine 143.7 19.4† 70.9 13.7* 83.4  14.3*†
Norleucine 386.1 7.3 396.4 4.6 382.5  6.8
Proline 729.9 84.5† 324.3 47.7* 481.9  116.9*†
Serine 402.6  36.9† 170.8 23.9* 222.8  33.5*
Taurine 148.5 32.1 141.6 13.4 276.6  72.9
Threonine 600.9 123.8† 240.5 50.8* 266.2  49.9*
Tryptophan 33.8 3.9† 23.8 2.6* 20.7  3.5*
Tyrosine 366.9 24.4† 224.3 39.8* 213.6  42.3*
Valine 726.8  84.4† 394.2 24.4* 467.6  37.4*
Values are means  SE. *†Values are significantly different.
Fig. 3. Activity of digestive enzymes in the proximal and distal remnant small intestine. A–C: activity of disaccharidases (sucrase, maltase, lactase). D–F: activity
of peptidases [dipeptidyl peptidase-4 (DPPIV), aminopeptidase N (ApN) and aminopeptidase A (ApA)]. Data are presented as means SE. Significant difference
between groups (*P  0.05; ***P  0.001).
G282 GLP-2 IN PEDIATRIC SBS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00064.2013 • www.ajpgi.org
 by 10.220.33.3 on February 5, 2017
http://ajpgi.physiology.org/
D
ow
nloaded from
 
that GLP-2 can be used to improve nutrient availability, fluid
loss, and possibly growth in the highly vulnerable infant
patients with SBS group. Continuous infusion of the native
peptide with TPN was sufficient to mediate the effect in
preterm pigs, but it remains to be tested whether long-acting
GLP-2 analogs or GLP-2 combined with early minimal enteral
nutrition will have the potential to exhibit the same effects in
this model and possibly in infants too.
In our model, a jejunostomy was made to specifically study
nutrient balance without a functioning colon, which reflects the
clinical situation of newly resected infants with limited colon
stimulation and thus endogenous GLP-2 secretion. The insuffi-
cient intestinal adaptation in preterm SBS pigs likely reflects
insufficient endogenous GLP-2 secretion with much lower values
in the SBS pigs (14  2 pM), relative to the unresected control
pigs (34  3 pM) or intact TPN-fed term piglets (35  4 pM)
observed previously (3). After introduction of enteral nutrition
during the balance study period, the SBS pigs showed no increase
in GLP-2 (19 3 pM), whereas the levels increased sharply in the
control pigs (63  9 pM, Fig. 1B), indicating that SBS preterm
pigs were unable to mount a GLP-2 secretion response to enteral
feeding. In more mature rodents (27), pigs (29), and humans (24),
jejunal resection with a reconnected colon leads to elevated
plasma GLP-2 levels. Even if the ileum is resected and the colon
remains in continuity with the remnant intestine, GLP-2 levels are
still increased (21), and this endogenous colonic GLP-2 release
may significantly improve intestinal adaptation (6, 26, 44). Our
results suggest that, under the clinically relevant conditions of
SBS with a jejunostomy, endogenous GLP-2 deficiency leads to
limited adaptation of the remnant intestine in the premature
neonatal intestine. In addition, the limited adaptation may be
explained by the immature state of the preterm intestine. We have
previously documented enhanced intestinal adaptation in term
SBS pigs with a jejunostomy, relative to preterm SBS pigs (38).
Our results show that exogenous GLP-2 partly restored
intestinal structure and function in preterm pigs with SBS and
Fig. 4. A–C: small intestinal volume, villus height, and crypt depth. D: Ki67-positive cells per crypt area. E: Western blot of proliferating cell nuclear antigen
(PCNA) and cleaved caspase 3. F: representative hematoxylin-eosin sections of the small intestine in control, SBS, and SBSGLP-2, respectively. Significant
difference between groups (*P  0.05; ***P  0.001).
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a jejunostomy. The pharmacological increase in circulating
GLP-2 levels resulted in a remarkable increase in the total
intestinal mass and protein and DNA content of the remnant
intestine to levels that approached the value in unoperated pigs.
The changes in tissue mass were matched by increases in
volume of mucosa, villus height, and crypt depth, indicating
rapid structural changes associated with GLP-2 treatment sim-
ilar to or even more pronounced than those reported in adult
SBS models (10, 27). The changes were supported by parallel
increases in protein synthesis, like in intact newborn pigs (3,
4), and increased circulating arginine, ornithine, and citrulline
levels. The increase in epithelial cell mass leads to increased
plasma citrulline, which is further metabolized to arginine (13,
45) despite that total levels of essential amino acids were
decreased in both resection groups. This may be explained by
the fact that protein absorption was only 60–80% of oral
supply, similar to observations from infants with a jejunostomy
(39). This may lead to lower circulating free amino acids, even
with GLP-2 stimulation of absorption.
Despite the increased intestinal mucosal villus height, crypt
depth, and total volume, we did not see an increased prolifer-
ation after GLP-2 treatment, contrasting some other reports (3,
4, 27, 29). However, the results are in agreement with previous
findings in preterm TPN-fed pigs, where increased villus
height was not associated with increased proliferation (30).
Ki67 staining is a static marker of crypt cell proliferation, and
exogenous GLP-2 may have stimulated cell proliferation and
fractional rates of total protein synthesis mainly during the first
days following resection; secondly high basal proliferation
following enteral nutrition in preterms may hide GLP-2 effects.
A detailed description of the specific SBS-and GLP-2-medi-
ated changes in intestinal proteins will be presented as a
separate report based on the gel-based proteomics analyses of
intestinal tissues from the present study.
The trophic response to GLP-2 translated into significant
improvements in clinically relevant indices of intestinal ab-
sorptive function. The increase in brush border enzyme activ-
ities, particularly sucrase and maltase in GLP-2-treated pigs, is
in agreement with previous findings in rodents (40) and unre-
sected preterm and term pigs (30, 31). On the other hand,
GLP-2 had no effect on tissue-specific nutrient (glucose, leu-
cine) transport and in vivo galactose uptake, which is consis-
tent with our previous findings, showing hyporesponsiveness
in fetal and preterm compared with term piglets (34, 37, 38).
Further studies are needed to investigate whether it would be
possible to utilize the increased relative enteral absorption,
reported in the current study, to decrease the parenteral sup-
port, as has been shown with GLP-2 to adults (19). The
ultimate goal would of course be to wean neonates with
intestinal resection off TPN, but more long-term studies are
needed to investigate this. Furthermore studies are warranted to
investigate whether various GLP-2 treatment regimens, with or
without concurrent enteral nutrition, can augment intestinal
adaptation and function to treat intestinal failure in pediatric
patients.
In conclusion, we show novel evidence in parenterally fed,
preterm piglets in which SBS with a jejunostomy induces a
GLP-2-deficient state and limited intestinal adaptation. We
also show that GLP-2 treatment effectively induces intestinal
adaptation, even under conditions of exclusive parenteral nu-
trition. Moreover, the intestinal trophic effect of 5 days of
GLP-2 treatment translated into an increased intestinal absorp-
tive function during the first 24 h of enteral feeding after
resection. These results extend our previous evidence that
GLP-2 exerts trophic effects in preterm neonates and suggest
that GLP-2 treatment is a promising therapy to maintain
intestinal function in neonatal patients immediately after intes-
tinal resection.
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